Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference
January 04 2019 - 9:00AM
Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a
cutting-edge biotechnology company developing new treatments for
life-threatening medical conditions by improving the body’s ability
to bring oxygen to the areas where it’s needed most, announced
today that Chief Executive Officer David Kalergis will join
investors, executives, civic leaders, and scientists to present at
the 37th Annual J.P. Morgan Healthcare Conference on Monday,
January 7, 2019 at 7:00pm EST/4:00pm PST. The Conference will be
held on January 7-10, 2019 at the Westin St. Francis Hotel in San
Francisco, California.
“Advancements in the biotechnology,
pharmaceutical, and medical industries don’t happen in a vacuum;
they require collaboration between investors, scientists, and
business leaders,” said David Kalergis,
Chairman and CEO of Diffusion. “Diffusion was founded in
that same spirit of collaboration, and at the 37th Annual J.P.
Morgan Healthcare Conference, we’ll have the opportunity to share
our progress with an even larger audience of leaders who can
potentially work with us to fuel life and fight deadly conditions
such as cancer and stroke.”
The “largest and most informative healthcare
investment symposium in the industry,” the J.P. Morgan Healthcare
Conference brings together “industry leaders, emerging fast-growth
companies, innovative technology creators, and members of the
investment community.” Over 9,000 attendees and representatives
from over 450 public and private companies have had the chance at
past conferences to hear from speakers including Bill Gates, Vice
President Joe Biden, and CEO of 23andMe Anne Wojcicki. To listen to
Mr. Kalergis’s presentation live, you can go to the Investor
Relations section of the Diffusion Pharmaceuticals website at
www.diffusionpharma.com. An archived webcast of the presentation
will also be available on the Company’s website for a period of
time.
About Diffusion Pharmaceuticals
Inc.
Diffusion Pharmaceuticals Inc. is an innovative
biotechnology company developing new treatments that improve the
body’s ability to bring oxygen to the areas where it’s needed
most—offering new hope for the treatment of life-threatening
medical conditions.
Diffusion’s lead drug, Trans Sodium Crocinate
(TSC), was originally developed in conjunction with the Office of
Naval Research, which was seeking a way to treat hemorrhagic shock
caused by massive blood loss on the battlefield.
Evolutions in research have led to Diffusion’s
focus today: Fueling Life by taking on some of medicine’s most
intractable and difficult-to-treat diseases, including stroke, GBM
brain cancer, pancreatic cancer, and brain metastases. In each of
these diseases, hypoxia—when essential tissue in your body is
deprived of oxygen—has proved to be a significant obstacle for
medical providers and the target for TSC’s novel mechanism.
In 2018, the Company began enrolling patients in
its Phase 3 INTACT program, using TSC to target inoperable GBM
brain cancer. Its on-ambulance Phase 2 acute stroke protocol was
granted FDA clearance to proceed in September, 2018.
Additional pre-clinical data supports the potential use of TSC as a
treatment for other conditions where hypoxia plays a major role,
such as myocardial infarction, respiratory diseases such as COPD,
peripheral artery disease, and neurodegenerative conditions such as
Alzheimer’s and Parkinson’s.
In addition, RES-529, the Company’s
PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and
mTORC2 complexes, is in the preclinical testing phase for GBM.
Diffusion is headquartered in Charlottesville,
Virginia—a hub of advancement in the life science and
biopharmaceutical industries and is led by CEO David Kalergis, a
30-year industry veteran and company co-founder.
Forward-Looking Statements
To the extent any statements made in this news
release deal with information that is not historical, these are
forward-looking statements under the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about the company's plans, objectives,
expectations and intentions with respect to future operations
and products, the potential of the company's technology and product
candidates, the anticipated timing of future clinical trials, and
other statements that are not historical in nature, particularly
those that utilize terminology such as "would," "will," "plans,"
"possibility," "potential," "future," "expects," "anticipates,"
"believes," "intends," "continue," "expects," other words of
similar meaning, derivations of such words and the use of future
dates. Forward-looking statements by their nature address matters
that are, to different degrees, uncertain. Uncertainties and risks
may cause the company's actual results to be materially different
than those expressed in or implied by such forward-looking
statements. Particular uncertainties and risks include: general
business and economic conditions; the company's need for and
ability to obtain additional financing or partnering arrangement;
the difficulty of developing pharmaceutical products, obtaining
regulatory and other approvals and achieving market acceptance; and
the various risk factors (many of which are beyond Diffusion’s
control) as described under the heading “Risk Factors” in
Diffusion’s filings with the United States Securities and Exchange
Commission. All forward-looking statements in this news release
speak only as of the date of this news release and are based on
management's current beliefs and expectations. Diffusion undertakes
no obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Contact:Rob Corradi Pen Public
Affairsrob@penpublicaffairs.com410-212-5483
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Apr 2023 to Apr 2024